Empagliflozin Improves Outcomes in Patients with Heart Failure and Preserved Ejection Fraction Irrespective of Age (JACC July 2022-1)

Empagliflozin Improves Outcomes in Patients with Heart Failure and Preserved Ejection Fraction Irrespective of Age (JACC July 2022-1) is organized by American College of Cardiology (ACC).,Date of Release: June 27, 2022,Term of Approval/Date of CME/MOC/ECME Expiration: June 26, 2023,Description:,The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).,Additional details will be posted as soon as information is available.